Free tool
FAERS Monitor: Alecensa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208434 or its brand name (Alecensa, Alectinib Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
7,388
Serious
4,065
55% of reports
Hospitalization
1,310
Death reported
951
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death718
- fatigue526
- no adverse event472
- off label use472
- constipation455
- rash267
- dyspnoea240
- disease progression216
- weight increased213
- myalgia212
- asthenia200
- peripheral swelling180
- drug ineffective173
- nausea167
- pain163
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 125 |
| 2017 | 255 |
| 2018 | 529 |
| 2019 | 589 |
| 2020 | 878 |
| 2021 | 704 |
| 2022 | 759 |
| 2023 | 743 |
| 2024 | 1,856 |
| 2025 | 541 |
| 2026 | 409 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,771 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| no adverse eventSignal | 472 | 7.4 | 6.8 | 2,637 |
| constipationSignal | 455 | 5.9 | 5.4 | 1,884 |
| disease progressionSignal | 216 | 5.2 | 4.6 | 732 |
| myalgiaSignal | 212 | 3.6 | 3.1 | 389 |
| peripheral swellingSignal | 180 | 3.3 | 2.9 | 293 |
| weight increasedSignal | 213 | 2.7 | 2.4 | 230 |
| deathSignal | 718 | 2.4 | 2.2 | 593 |
| fatigue | 526 | 1.9 | 1.8 | 241 |
| rash | 267 | 1.7 | 1.6 | 86 |
| off label use | 472 | 1.5 | 1.4 | 91 |
| asthenia | 200 | 1.5 | 1.3 | 35 |
| dyspnoea | 240 | 1.2 | 1.1 | 9 |
| pain | 163 | 0.8 | 0.6 | 13 |
| nausea | 167 | 0.6 | 0.5 | 46 |
| drug ineffective | 173 | 0.4 | 0.3 | 193 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.